Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

• DOI: 10.3389/fphar.2021.711813
• Publication Date: 2021-09-20T16:41:36Z
• Authors: Dominique Berton; Anne Floquet; Willy Lescaut; Gabriel Baron; Marie-Christine K...; Philippe Toussaint; Rémy Largillier; Aude-Marie Savoye; Jérôme Alexandre; Catherine Delbaldo; Emmanuelle Malaurie; Hugues Barletta; Claire Bosacki; Claire Garnier-Ti...; Philippe Follana; Hortense Laharie-...; Charles Briac Lev...; Bruno Valenza; Agnès Dechartres; Delphine Mollon-G...; Frédéric Selle
• Keywords: Interquartile range; Carboplatin

Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study assessed treatment administration and outcomes in the French real-world setting. Patients Methods: Eligible patients were aged ≥ 18 years with planned bevacizumab-containing newly diagnosed cancer. primary objective was to assess safety profile bevacizumab routine clinical practice; secondary objectives describe patient characteristics, indications/contraindications bevacizumab, regimens co-medications, follow-up monitoring, progression-free survival, at recurrence. In this study, administered as chosen by investigator participation trial had no influence management disease. Results: Of 1,290 screened between April 2013 February 2015, 468 eligible. Most (86%) received 15 mg/kg every weeks or equivalent, typically carboplatin (99%) paclitaxel (98%). median duration 12.2 (range 0–28, interquartile range 6.9–14.9) months; 8% discontinued because toxicity. most common adverse events hypertension (38% patients), fatigue (35%), bleeding (32%). There treatment-related deaths. physicians (90%) reported blood pressure measurement immediately before each infusion almost all (97%) monitoring proteinuria infusion. Median survival 17.4 (95% CI, 16.4–19.1) months. 3-year overall rate 62% 58–67%). commonly chemotherapies recurrence pegylated liposomal doxorubicin. Discussion: Clinical tolerability real-life setting are consistent results, notwithstanding differences treated population schedule. Trial Registration: ClinicalTrials.gov , Identifier NCT01832415.